Research Article
Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States
Table 2
Key input parameters.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AE = adverse event; AIM = ifosfamide + doxorubicin + mesna; BSA = body surface area; Dex = dexamethasone; Doc = docetaxel; Dox = doxorubicin; DTIC = dacarbazine; G-CSF = granulocyte-colony stimulating factor; Gem = gemcitabine; GemDoc = gemcitabine + docetaxel; HCPCS = Healthcare Common Procedure Coding System; Ifo = ifosfamide; MAID = mesna + doxorubicin + ifosfamide + dacarbazine; Olara = olaratumab; Olara+Dox = olaratumab + doxorubicin; PLD = pegylated liposomal doxorubicin; RBRVS = resource-based relative value scale; SD = standard deviation; UK = United Kingdom. aThe mean (SD) weight and BSA were assumed to be 85.8 (23.0) kg and 2.0 (0.3) m2 (JGDG trial, Lilly data on file [33]). Drug costs were calculated by assuming that unused drug in opened vials is wasted. The distribution of weight and BSA was simulated, and the number of vials needed for each weight per BSA category was determined and costed. bAlso day 1 after Dox discontinuation (Olara only). cAssumed to be given in an outpatient setting. dOutpatient visit and physical examination ($223.03); computerized tomography scan ($352.78; 92% of visits); positron emission tomography ($1,072.98; 9% of visits); magnetic resonance imaging ($584.29; 14% of visits). Source of unit costs: Essential RBRVS [31] HCPCS codes; usage of imaging based on Lilly observational study [32] (UK data). eBased on clinical expert opinion. fEssential RBRVS [31] HCPCS codes. gCosts were estimated based on subsequent lines of treatment observed after the investigational therapy in the JGDG study in each treatment arm. Subsequent therapies included DTIC, GemDoc, Dox, eribulin, everolimus, Gem, Ifo, Ifo + mesna, pazopanib, and trabectedin. The average cost of treatments in the Olara + Dox arm was applied for both arms. The total cost of all subsequent treatments recorded in the trial was estimated based on the proportion of patients receiving each regimen and duration of therapy recorded. Drug and administration costs were estimated assuming a 3-week treatment cycle and dosing schedules from clinical studies; unit costs were from Micromedex Solutions [30] and HCPCS codes from Essential RBRVS [31]. |